The Medical Letter on Drugs and Therapeutics
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved cangrelor (Kengreal – The Medicines Company), an IV P2Y12 platelet inhibitor, as an adjunct to percutaneous coronary intervention (PCI) in patients who have not been pretreated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

ANTIPLATELET DRUGS FOR PCI — Current guidelines recommend aspirin plus an oral P2Y12 inhibitor, either clopidogrel (Plavix, and generics), prasugrel (Effient), or ticagrelor (Brilinta), for all patients undergoing PCI.1,2 For prevention of myocardial infarction (MI) and stent thrombosis in patients with acute coronary syndrome, both prasugrel and ticagrelor have been more effective than clopidogrel, but with a higher incidence of bleeding. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI
Article code: 1480a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian